Project Grant R01AI194555
Award Date
8/1/25
Completion Date
7/31/29
Dollars Obligated
$3.1M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Utah, USA
Similar Awards
The University of Utah was awarded a $423,500 Project Grant by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The 3-year grant, running from July 1, 2025 to June 30, 2027, will fund the development and evaluation of a novel "3-in-1" chimeric antigen receptor T regulatory cell (CAR Treg) design targeting effector T cells expressing programmed death-1 (PD-1). This innovative...
This $423,500.00 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research at the University of Utah to investigate the role of invariant natural killer T (iNKT) cells in shaping the immune response to Plasmodium infection, which can lead to the severe neurological condition of cerebral malaria. The research aims to define how the T cell receptor (TCR) signaling properties of different iNKT cell...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to elucidate the mechanisms by which influenza infection can protect against malaria-associated respiratory distress syndrome (MA-ARDS) in mice. The $224,070 award to the University of Utah aims to determine how influenza modifies pulmonary vascular endothelial cells and induces arginase 1-producing...
The federal Project Grant award R01AI186945 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) for $625,348 with a period of performance from Jul 3, 2025 to Jun 30, 2030. The grant supports research at the University of Utah to define the role of the NF-kB signaling network in regulating affinity maturation and the generation of plasma cells and memory B cells. The goal is to improve...
This $415,250 federal Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research conducted by the University of Rochester to investigate the role of a novel myeloid cell type, long-lived highly differentiated monocyte-derived cells (LDMs), in regulating lung-resident memory T cell (Trm) responses to recurrent influenza virus infection. The key objectives are to determine...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,863,501.00 over a 4-year period starting August 1, 2025 to conduct research on the mechanisms of CD4 T cell help to myeloid cells in tuberculosis (TB). The research aims to define how CD4 T cells, through direct cell-cell contact and indirect pathways, activate myeloid cells to control intracellular Mycobacterium...
This federal Project Grant award, valued at $472,210.00 and effective June 23, 2025 through May 31, 2027, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research by the University of Massachusetts Medical School to investigate the spatiotemporal relationship between CD4+ T resident memory cells and neutrophil recruitment in the lungs during pneumonia in experienced...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $785,511 to the University of Chicago to conduct research on the genetic and epigenetic basis of inter-individual variation in immune responses to two deadly infectious agents, Mycobacterium tuberculosis and influenza virus. The key objectives are to: (1) characterize variability in immune responses to these...
This federal Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,225,986.00 to the University of Chicago to conduct research on the adaptive immune response to influenza vaccination. The goal is to develop computational models that describe the conditions leading to strong, durable, and broadly protective immune responses, particularly in individuals with prior...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $230,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute. The purpose of this 2-year grant, with a start date of January 23, 2025, is to evaluate recently discovered neuraminidase broadly neutralizing antibodies (NA BnAbs) for their potential use in a universal influenza vaccine. The research will assess factors such as precursor frequency,...